Navigation Links
Novel Vaccines Improve Potential for European Vaccines Manufacturers
Date:1/14/2009

eal with government policies, perceptions and awareness levels that diverge widely across Europe.

"A clear comprehension about the dynamics in various regions is important to predict demand and alter business strategies accordingly," explains Paul. "Predicting and meeting demand is one of the most challenging factors in the vaccines industry. Efficiency in manufacturing and distribution has to be achieved in order to offset limited production capacities and low profit margins."

Keeping abreast of epidemiological trends and government policies, coupled with efforts to boost physician and public awareness, will be crucial. In the context of R&D, the identification of the disease areas to be targeted, through a vaccine or a combination, is important because market penetration and revenue generation are largely dependent upon these factors in various regions.

"Vaccine manufacturers should be able to identify key market dynamics, promote efficiency of operation and support public perception while adapting and implementing lean principles and innovative marketing strategies," advises Paul. "Streamlining investments into R&D of adjuvant technologies, therapeutic and DNA vaccines could enable realisation of significant potential in these areas."

If you are interested in a virtual brochure, which provides manufacturers, end users and other industry participants with an overview of the European vaccines market, then send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by e-mail.

European Vaccines Market is part of the
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. University of Ottawa Heart Institute Scientists Successfully Develop Novel Biomaterial to Help Grow New Blood Vessels
2. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
3. Frost & Sullivan Lauds Toscana Biomarkers Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
4. BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
5. Novel prostate cancer vaccine taking aim at cancer cell sweet spot
6. Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
7. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
8. Mutations common to cancer and developmental disorder examined in a novel disease model
9. Labopharm to host webcast presentation on novel trazodone formulation - tomorrow (Dec.16/08) at 10:00 a.m. ET
10. Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
11. FDA Grants NeoVistas Request to Utilize Novel Wet AMD Treatment in Compassionate Case
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 2Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 3Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 4Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 5Trubion and Facet Biotech Announce Presentation of Positive TRU-016 Data at the 2009 ASH Annual Meeting 6CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2MRI Accurately Depicts Deep Endometriosis 50849 1MRI Accurately Depicts Deep Endometriosis 50849 2MRI Accurately Depicts Deep Endometriosis 50849 3Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction 50847 1Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction 50847 2Vivacare Patient Education Service Enhancements Save Medical Practices Time and Money and Improve Patient Satisfaction 50847 3Multimedia Release 3A British Men Think Talking About Impotence is 22Just Not Cricket 22 50845 1Multimedia Release 3A British Men Think Talking About Impotence is 22Just Not Cricket 22 50845 2Multimedia Release 3A British Men Think Talking About Impotence is 22Just Not Cricket 22 50845 3Multimedia Release 3A British Men Think Talking About Impotence is 22Just Not Cricket 22 50845 4Multimedia Release 3A British Men Think Talking About Impotence is 22Just Not Cricket 22 50845 5